Patient preferences for obesity treatments highlight efficacy, administration, and side effects as key drivers for adherence.

Obesity is a complex, chronic disease linked to severe complications like type 2 diabetes and cardiovascular disease. While lifestyle interventions are foundational, pharmacotherapy is often necessary for effective management. Historically, older weight management drugs offered limited efficacy and problematic safety profiles, leading to underutilization and poor long-term adherence. The recent advent of incretin-based therapies, such as GLP-1 receptor agonists, has introduced more efficacious and safer options. However, despite these advancements, challenges persist in ensuring sustained treatment adherence and integrating pharmacotherapy into holistic care. Understanding patient preferences regarding treatment attributes like efficacy, mode of administration, convenience, and side effects is crucial to bridge this gap and improve patient-centered care and treatment persistence.

This study, titled 'The VOICE study', aimed to understand patient preferences for pharmacological treatments for obesity. As only the introduction is available, specific details on the methodology, such as participant demographics, recruitment strategies, the exact study design (e.g., a discrete choice experiment or survey instrument), sample size, or data collection methods, are not described in this excerpt. The study's focus was on attributes like efficacy, mode of administration, convenience, and side effects.

The provided abstract/text does not contain specific findings or numerical results from the VOICE study.